Navigation Links
Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
Date:7/13/2008

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech as Vice President of Medicinal Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientific experience and proven leadership capability to his new role in WuXi. Prior to joining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego based biotechnology company, as Vice President of Research and Development and Chief Scientific Officer from March 2003 to March 2008. Before joining TargeGen, Dr. Soll held senior positions with increasing responsibilities at Ontogen Corporation and 3-Dimensional Pharmaceutical, Inc.

Dr. Soll is well recognized and respected for his scientific acuity from the academic and industry circles. Amongst his most recent achievements are first-in-class drug development nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders.

As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services platform. Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very excited to welcome Dr. Soll on board to lead and expand our already strong medicinal chemistry unit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi, Rich has a unique perspective on how to maximize service value creation for clients. His broad experience in the pharmaceutical industry and proven track record as a leader make him an ideal fit for the organization. I am confident that under his leadership our medicinal chemistry service capability will be stronger and further integrated with those of other services."

Dr. Soll received his B.S. in Chemistry from the University of Massachusetts, Massachusetts and his Ph.D. in Chemistry from Dartmouth College, New Hampshire. He was also a chemistry post-doctoral fellow at Harvard University with Professor E. J. Corey.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award
3. Chicago Mayor Richard M. Daley to Address the 7th Annual Compliance and Ethics Institute
4. MultiVu Video Feed: Richard Simmons and Ocean Spray Team-Up to Solve
5. Stop Obesity Alliance, Chair Dr. Richard H. Carmona, National Opinion Research Center Reveal Findings of Survey Showing Employer Concern About Health, Financial Costs of Obesity
6. Veterans Honor Dr. Richard Merkin During Research Week
7. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
8. Richard T. Clark Elected PhRMA Board Chairman
9. Danny Calegari Appointed the Richard Merkin Distinguished Professor of Mathematics at the California Institute of Technology
10. Kevin Richardson Named Vice President, Sales, National & Multi-State Business for Kaiser Permanente
11. AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: